Correction to: “Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study” - Scorecard - MDSpire
Clinical Scorecard: Comparative Cardiovascular Safety of Romosozumab and PTH Analogues in Osteoporosis Management: A Propensity-Score-Matched Analysis (Erratum)
At a Glance
Category
Detail
Condition
Osteoporosis
Key Mechanisms
Romosozumab and PTH analogues impact bone metabolism; no established pathophysiologic pathway linking romosozumab to cardiovascular effects
Target Population
Patients with osteoporosis
Care Setting
Clinical management of osteoporosis
Key Highlights
Correction issued regarding in-text reference citations in the original article.
No established biological mechanism currently explains a cardiovascular link with romosozumab.
Reference citations 46-51 were removed from the discussion due to absence in the reference list.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients receiving romosozumab or PTH analogues for osteoporosis
No new evidence supporting cardiovascular risk mechanisms for romosozumab; clinical decisions should consider current safety data.
Clinical Best Practices
Verify reference citations carefully to ensure accuracy in clinical publications.
Recognize that current evidence does not establish a cardiovascular risk mechanism for romosozumab.
Continue monitoring emerging data on cardiovascular safety in osteoporosis treatments.
Teriparatide followed by zoledronic acid increased bone mineral density but did not reduce fracture risk compared with standard care in adults with osteogenesis imperfecta.
